Refractory Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation (S34.008)
Our objective is to report on the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) in refractory myasthenia gravis.
Authors
- Kareem Jamani (ORCID: https://orcid.org/0000-0001-7612-522X)
- Pierre R. Bourque (ORCID: https://orcid.org/0000-0002-7455-0254)
- Benjamin Béland (ORCID: https://orcid.org/0000-0002-9574-1412)
- Christopher Bredeson (ORCID: https://orcid.org/0000-0002-9689-5114)
- Natasha Kekre (ORCID: https://orcid.org/0000-0001-8394-0855)
- Harold Atkins
- Christopher Hahn (ORCID: https://orcid.org/0009-0001-7617-6374)
- Chris White (ORCID: https://orcid.org/0000-0002-7732-2206)
- Michael Kennah
- Elizabeth Pringle
- Jan Storek (ORCID: https://orcid.org/0000-0002-7884-9122)
- Liam Quartermain
Institutions
- University of Ottawa (CA)
- University of Calgary (CA)
- South Health Campus (CA)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208402
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00